ADC Therapeutics
ADCT
115 hedge funds and large institutions have $293M invested in ADC Therapeutics in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 48 increasing their positions, 27 reducing their positions, and 12 closing their positions.
1,771% more call options, than puts
Call options by funds: $131K | Put options by funds: $7K
78% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 27
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
8% more funds holding
Funds holding: 106 → 115 (+9)
8% more capital invested
Capital invested by funds: $271M → $293M (+$21.5M)
6.6% more ownership
Funds ownership: 60.3% → 66.89% (+6.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$40.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$13.7M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$13M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$4.08M |
| 5 |
BlackRock
New York
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.7M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$5.3M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.73M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.12M |
| 5 |
Millennium Management
New York
|
-$1.51M |
ADCT Hedge Fund Activity: Q4 2025 in Review
115 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2025, worth a combined $293M — up 7.9% from $271M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ADCT positions and 12 closed out — a net gain of 9 holders — while 48 added to existing stakes and 27 trimmed.
The largest buyer was TCG Crossover Management, adding an estimated $40.6M. The largest seller was Point72 Asset Management, cutting an estimated $12.7M.
- 115 institutional investors held ADC Therapeutics (ADCT) as of Q4 2025, up from 106 in Q3 2025.
- Funds reported $293M of ADC Therapeutics stock for Q4 2025, up 7.9% quarter-over-quarter.
- 21 funds opened new ADC Therapeutics positions in Q4 2025 and 12 closed out, a net change of +9 holders.
- The largest ADC Therapeutics buyer in Q4 2025 was TCG Crossover Management, an estimated $40.6M added.
- The largest ADC Therapeutics seller in Q4 2025 was Point72 Asset Management, an estimated $12.7M sold.
Based on aggregated 13F filings for Q4 2025.